The incidence of cardiac surgeries is increasing world-wide in view of the demographic change. Cardiac surgery carries a significant amount of risk as on average 60% of patients develop postoperative atrial fibrillation, by far the most frequently occurring complication after cardiac surgery. Clinical investigations show a significant increase in morbidity, mortality and duration of treatment and hospital stay. The risk for stroke is increased 3-fold! From all discussions with renowned surgeons results the clear statement that an avoiding or reduction of medical drugs is in any circumstance a preferable and desirable ambition. The DefiPace™ system is a proven and awaited method by the physicians treating post-operative patients. Our new system is unique, as it is the only system in history and today, which allows physicians to prevent and terminate postoperative atrial fibrillation (POAF) in all patients. It is the only system which combines standard stimulation, bi-atrial pacing as well as epicardial low-energy cardioversion in one hand-held easy-to-use device even on general ward. Target customers are all patients undergoing cardiac surgery world-wide (market volume: € 1.5 billion). Advantages: Simplicity • TMA pacing & cardioversion wires: easy to use, similar to standard pacing wires • DefiPace device: Intuitive handling for clinical staff similar to standard external pacemakers Prevention and Termination: • Bi-atrial pacing as an effective way to prevent POAF • Quick Termination of atrial fibrillation with safe, elegant low energy cardioversion • No anesthesia necessary Cost savings for surgical clinics • Significant cost savings: at least €1,000per day/patient Improved health • Few or no medication required • All complications from atrial fibrillation can be completely avoided The DefiPace™-System is as a key product for OSYPKA and will lead to significant increase of sales and employees. We will revolutionize the pacemaker market a second time in our history